Molecular mechanisms of altered bile acid homeostasis in organic solute transporter-alpha knockout mice

Tian Lan1, Jamie Haywood, Anuradha Rao

  • 1Department of Internal Medicine, Section on Gastroenterology, Wake Forest University School of Medicine, Winston-Salem, N.C., USA.

Abstract

Insights

Blocking the farnesoid X receptor (FXR) in mice with impaired bile acid transport corrected bile acid homeostasis. This suggests FXR signaling contributes to bile acid malabsorption phenotypes.

Area of Science:

  • Hepatology and Gastroenterology
  • Molecular Biology
  • Metabolic Diseases

Background:

  • Mutations in bile acid transporters disrupt intestinal absorption, leading to altered bile acid homeostasis.
  • Inactivating the basolateral bile acid transporter (OSTα-OSTβ) impairs absorption but paradoxically represses hepatic bile acid synthesis.
  • Ileal bile acid trapping via farnesoid X receptor (FXR) and FGF15 signaling is hypothesized to cause this repression.

Purpose of the Study:

  • To investigate the role of FXR signaling in the bile acid homeostasis defect observed in Ostα null mice.
  • To determine if blocking FXR signaling can reverse the repressed hepatic bile acid synthesis phenotype.

Main Methods:

  • Generation of OstαFxr double-null mice by crossbreeding Ostα null and Fxr null mice.
  • Comparison of wild-type, Ostα null, Fxr null, and OstαFxr double-null littermates.
  • Analysis of bile acid fecal excretion, pool size, composition, and gene/protein expression in liver and intestine.

Main Results:

  • OstαFxr null mice showed increased fecal bile acid excretion and pool size, with reduced pool hydrophobicity compared to Ostα null mice.
  • FXR inactivation reversed increased ileal FGF15 expression.
  • Significant increase in hepatic Cyp7a1 expression was observed following FXR inactivation.

Conclusions:

  • Blocking FXR signaling largely corrected the bile acid homeostasis defect in Ostα null mice, unmasking the malabsorption phenotype.
  • Inappropriate activation of the FXR-FGF15-FGFR4 pathway contributes to the observed phenotype.
  • FXR is not required for adaptive intestinal morphological changes or reduced apical sodium-dependent bile acid transporter expression.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Membrane Asymmetry Regulating Transporters01:19

Membrane Asymmetry Regulating Transporters

Enzymes like flippase, floppase, and scramblase transfer phospholipids from one layer to another in the membrane, thereby affecting membrane asymmetry.
Flippase
Eukaryotic flippases are type-IV P-type ATPases or P4-ATPases belonging to P-type ATPase family proteins that are membrane-bound pumps involved in the ATP-mediated transport of ions and molecules across the membrane. Flippases flip specific phospholipids from the outer to the inner leaflet of a membrane. All P4-ATPases have one...